Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview)
Open Access
- 21 June 2010
- Vol. 2 (6), 1568-1581
- https://doi.org/10.3390/toxins2061568
Abstract
While intensive efforts have been made for the treatment of cancer, this disease is still the second leading cause of death in many countries. Metastatic breast cancer, late-stage colon cancer, malignant melanoma, multiple myeloma, and other forms of cancer are still essentially incurable in most cases. Recent advances in genomic technologies have permitted the simultaneous evaluation of DNA sequence-based alterations together with copy number gains and losses. The requirement for a multi-targeting approach is the common theme that emerges from these studies. Therefore, the combination of new targeted biological and cytotoxic agents is currently under investigation in multimodal treatment regimens. Similarly, a combinational principle is applied in traditional Chinese medicine, as formulas consist of several types of medicinal herbs or minerals, in which one represents the principal component, and the others serve as adjuvant ones that assist the effects, or facilitate the delivery, of the principal component. In Western medicine, approximately 60 different arsenic preparations have been developed and used in pharmacological history. In traditional Chinese medicines, different forms of mineral arsenicals (orpiment—As2S3, realgar—As4S4, and arsenolite—arsenic trioxide, As2O3) are used, and realgar alone is included in 22 oral remedies that are recognized by the Chinese Pharmacopeia Committee (2005). It is known that a significant portion of some forms of mineral arsenicals is poorly absorbed into the body, and would be unavailable to cause systemic damage. This review primary focuses on the application of arsenic sulfide (realgar) for treatment of various forms of cancer in vitro and in vivo.Keywords
This publication has 67 references indexed in Scilit:
- Mechanochemical preparation and anticancer effect of realgar As4S4 nanoparticlesMaterials Letters, 2009
- Metabolic profiling studies on the toxicological effects of realgar in rats by 1H NMR spectroscopyToxicology and Applied Pharmacology, 2009
- Resveratrol protects against arsenic trioxide‐induced cardiotoxicity in vitro and in vivoBritish Journal of Pharmacology, 2008
- Dissection of mechanisms of Chinese medicinal formula Realgar- Indigo naturalis as an effective treatment for promyelocytic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2008
- Biogenic formation of photoactive arsenic-sulfide nanotubes by Shewanella sp. strain HN-41Proceedings of the National Academy of Sciences of the United States of America, 2007
- Biogenic Mineral Production by a Novel Arsenic-Metabolizing Thermophilic Bacterium from the Alvord Basin, OregonApplied and Environmental Microbiology, 2007
- Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoproteinBlood, 2004
- Nuclear bodies and compartments: functional roles and cellular signalling in health and diseaseCellular Signalling, 2004
- Cell Proliferation and CD11b Expression Are Controlled Independently during HL60 Cell Differentiation Initiated by 1,25α-Dihydroxyvitamin D3 or All-trans-Retinoic AcidExperimental Cell Research, 2001
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideThe New England Journal of Medicine, 1998